179 related articles for article (PubMed ID: 16891455)
41. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
42. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
[TBL] [Abstract][Full Text] [Related]
43. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Lee HY; Lee JF; Kumar S; Wu YW; HuangFu WC; Lai MJ; Li YH; Huang HL; Kuo FC; Hsiao CJ; Cheng CC; Yang CR; Liou JP
Eur J Med Chem; 2017 Jan; 125():1268-1278. PubMed ID: 27886544
[TBL] [Abstract][Full Text] [Related]
44. Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma.
Tang H; Liang Y; Shen H; Cai S; Yu M; Fan H; Ding K; Wang Y
Bioorg Chem; 2022 Nov; 128():106112. PubMed ID: 36070628
[TBL] [Abstract][Full Text] [Related]
45. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
Bouchain G; Delorme D
Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
47. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
48. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
49. Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].
Lee JH; Yao Y; Mahendran A; Ngo L; Venta-Perez G; Choy ML; Breslow R; Marks PA
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12005-10. PubMed ID: 26371309
[TBL] [Abstract][Full Text] [Related]
50. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
52. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor.
Kong Y; Jung M; Wang K; Grindrod S; Velena A; Lee SA; Dakshanamurthy S; Yang Y; Miessau M; Zheng C; Dritschilo A; Brown ML
Mol Cancer Ther; 2011 Sep; 10(9):1591-9. PubMed ID: 21697394
[TBL] [Abstract][Full Text] [Related]
53. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases.
Brush MH; Guardiola A; Connor JH; Yao TP; Shenolikar S
J Biol Chem; 2004 Feb; 279(9):7685-91. PubMed ID: 14670976
[TBL] [Abstract][Full Text] [Related]
54. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
55. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
[TBL] [Abstract][Full Text] [Related]
56. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
57. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
59. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
Aldana-Masangkay GI; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Hsieh YT; Kim YM; Lomenick B; Okemoto K; Landaw EM; Wang D; Mazitschek R; Bradner JE; Sakamoto KM
Leuk Lymphoma; 2011 Aug; 52(8):1544-55. PubMed ID: 21699378
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]